Primary omental yolk sac tumor by 源��꽦�썕 et al.
www.ogscience.org412
Received: 2013.2.18.   Revised: 2013.6.13.  Accepted: 2013.6.18.
Corresponding author: Sunghoon Kim 
Department of Obstetrics and Gynecology, Yonsei University 
College of Medicine, 250 Seongsan-ro, Seodaemun-gu, Seoul  
120-752, Korea 
Tel: +82-2-2228-2230  Fax: +82-2-313-8357 
E-mail: shkim70@yuhs.ac
Articles published in Obstet Gynecol Sci are open-access, distributed under the terms of 
the Creative Commons Attribution Non-Commercial License (http://creativecommons.
org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, 
and reproduction in any medium, provided the original work is properly cited.
Copyright © 2013 Korean Society of Obstetrics and Gynecology 
Introduction
Yolk sac tumor is the second most common malignant germ 
cell tumor of ovary [1]. This tumor mainly occurs in female 
children and young women at the median age of 17.6 years. 
The main clinical symptom of yolk sac tumor is abdominal 
pain due to the large tumor volume (median size, 14 cm) [1]. 
The most characteristic pathologic finding of yolk sac tumor 
is Schiller-Duval body. The glomerular-like process exists in 
the empty space, and surrounded by tumor cells. The process 
has blood vessels in its center. This structure is observed in 
approximately 20% of yolk sac tumor. This structure is not es-
sentially contained for a diagnosis [2]. A a-fetoprotein (AFP) 
level provides important information on diagnosis, therapeutic 
effect and recurrence in patients with yolk sac tumor [2]. Yolk 
sac tumor rapidly grows and metastases via lymphatic and 
hematogenous route. Most of yolk sac tumors occur in ovary 
though rarely in extra-ovarian site including mediastinum, 
sacro-coccygeal region, cervix, vulva, pelvis and retroperito-
neum [1-3]. We herein report a case of primary yolk sac tumor 
of the omentum and literature review.
Case report
A 32-year-old woman was referred to this hospital because 
of developed low abdominal distension for a month. She got 
married at the age of 27 years and had no history of preg-
nancy. She had received diagnostic laparoscopy due to infertil-
ity in the past. Menstruation was regular with intervals of 26 
days with moderate volume of menstrual fluid and duration. 
In physical examination, a palpable mass with abdominal 
pain and tenderness was found in the right lower quadrant 
abdomen. CA-125 level was 364 U/mL (normal range, less 
than 35 U/mL). CA-19-9 level and carcinoembryonic antigen 
was in the normal range. 
Magnetic resonance imaging (MRI) showed a mass, about 
22 ×16 × 8 cm3 in size with ascites and peritoneal seeding 
nodules (Fig. 1). Findings of intravenous pyelogram, bladder 
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washing cytology, mammography, colonoscopy, and esopha-
go-gastro-duodenoscopy were negative. 
Explorative laparotomy was performed and an omental 
mass, about 23 ×15 ×10 cm3 in size, occupying whole ab-
domino-pelvic cavity was noted. As frozen biopsy of omentum 
showed a poorly differentiated tumor though whether it was 
primary or metastatic was uncertain, total abdominal hyster-
ectomy with bilateral salpingo-oophorectomy, bilateral pelvic 
lymph nodes dissection, paraaortic lymph nodes sampling, 
total omentectomy, and appendectomy were performed. 
Histopathological result of omental mass showed Schiller-
Duval body and both ovaries were not involved (Fig. 2). Right 
ovary was diagnosed as endometriotic cyst and left ovary was 
hemorrhagic corpus luteal cyst. AFP level at the postoperative 
day 7 was high (11,576.67 IU/mL) (normal range, less than 7 
IU/mL) though preoperative AFP was not measured. 
From the postoperative day 7, 6 cycles of postoperative 
adjuvant chemotherapy (bleomycin, etoposide, and cispla-
tin [BEP] regimen) with etoposide 100 mg/m2 and cisplatin 
Fig. 1. Magnetic resonance imaging (T2) finding. About 8×16×18 
cm sized mass is seen on pelvis. Ascites and peritoneal seeding 
nodules are suggested.
Fig. 2. Histological examination by H&E. Schiller-Duval body. The 
glomerular-like process exists in the empty space, and surrounded 
by tumor cells. The process has blood vessels in its center (A, ×100; 
B, ×200). Immunohistochemistry for alpha-fetoprotein (AFP). It re-
vealed a cytoplasmic expression of AFP in a subset of tumor cells (C, 
×40).
A  B
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20 mg/m2, each cycle lasting 3 days in combination with 6 
cycles of bleomycin 20 U/m2, each cycle lasting 1 day were 
performed every 3 weeks. In the follow-up after the first che-
motherapy, AFP level was found to have decreased to 1,746.15 
IU/mL (normal range, less than 7 IU/mL), and in the follow-up 
positron emission tomography-computed tomography (CT) at 
1 month after the sixth chemotherapy, abnormal hyperme-
tabolism suggestive of remnant tumor or metastasis was not 
observed and AFP level was normal with 2.04 IU/mL (normal 
range, less than 7 IU/mL). No recurrence was found during the 
4-year outpatient follow-up by CT and AFP level. 
Discussion 
Yolk sac tumor is a rare ovarian tumor and originates typically 
from reproductive organ. In 10% to 15% of the cases, how-
ever, it occurs extra-ovarian region including mediastinum, 
sacro-coccygeal region, cervix, vulva, pelvis and retroperi-
toneum, and more rarely in abdomen and retroperitoneum 
[1,4,5]. Tumors originating from extra-ovarian site can be ex-
plained by two major theories. First theory holds that tumors 
originating from extra-ovarian site occur as a result of aber-
rant differentiation of somatic cell. By this way, yolk sac tumor 
can occur in endometrium or stomach. Second theory holds 
that the tumors originating from extra-ovarian site occur as 
a result of misplacement of embryo migration in embryogen-
esis. In the second theory, germ cell is thought to be arrested 
or misplaced during the migration from cranial cavity, and 
consequently arrested in the bowel wall or the omentum. The 
second theory can explain about yolk sac tumor originating 
from omentum [3,5].
Definite diagnosis of yolk sac tumor can be made by surgi-
cal biopsy after evaluation of tumor marker and imaging test. 
Histological examination with specimen showed the Schiller-
Duval body, but Schiller-Duval body is not a essential for a di-
agnosis. Serum AFP level is a useful marker for diagnosis and 
treatment including diagnosis of recurrence [6]. In this case, 
change in postoperative AFP level has important meaning for 
treatment response. However, in the case of ovarian tumor se-
creting AFP, it is necessary to histologically distinguish it from 
other tumors such as hepatocellular carcinoma metastatic to 
the ovary, hepatoid carcinoma, hepatoid yolk sac tumor, and 
epithelial ovarian carcinoma. It should be confirmed that no 
abnormal finding in the liver is shown by re-reviewing the 
results of imaging test. Hepatoid yolk sac tumor originating 
from germ cells has been reported to often occur in children 
and young women. Meanwhile, hepatoid carcinoma has the 
same histologic findings, but mainly occurs in menopausal 
women. Hepatoid carcinoma is speculated to originate from 
the epithelial cells of the ovary. As it requires proactive treat-
ments due to poor prognosis, it is necessary to distinguish it 
from other ovarian tumors [7].
For the treatment of yolk sac tumor, surgical treatments, 
combined chemothrapy, and radiotherapy are used. As yolk 
sac tumor is unilateral, surgical treatment is performed uni-
lateral salpingo-oophorectomy. If metastasis or progression is 
observed after histological diagnosis confirmed, adnexectomy 
with debulking operation is conducted [7]. In this case, poorly 
differentiated tumor was observed in the patient who was 
young and nulliparous in a frozen biopsy after explorative 
laparotomy though whether it was primary or metastatic was 
uncertain. Thus, debulking operation including total abdomi-
nal hysterectomy with bilateral salpingo-oophorectomy was 
conducted instead of fertility-sparing surgery. 
Radiotherapy is ineffective, but postoperative combination 
chemotherapy is very effective in the treatment of yolk sac 
tumor. Currently, for germ cell tumor, BEP regimen is very ef-
fective in patients with initially completely resected tumor. 
Postoperative adjuvant chemotherapy (BEP regimen) with eto-
poside 100 mg/m2 and cisplatin 20 mg/m2, each cycle lasting 
5 days in combination with 3 to 4 cycles of bleomycin 30 U 
every weeks is performed in to 3 to 4 cycle every 3 weeks and 
at each cycle, serum AFP level is measured [8]. 
We herein report a case wherein surgical treatment com-
bined with combination chemotherapy was performed on a 
patient diagnosed with a rare yolk sac tumor that originated 
from omentum and 4-year outpatient follow-up thereafter 
showed that the treatment was successful. 
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